Asia Actual Hong Kong

Eric Leung
Asia Actual Hong Kong

“This scheme allows products with 2 Reference Country approvals and no serious adverse events to be reviewed quicker.”

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

Did you know that you can use R.O.S.E. to search what products are registered in Hong Kong?

It also allows you to search registered products in Singapore, Malaysia, Indonesia, Philippines, and Australia with more markets coming soon.

Hong Kong’s MDD Formalizes the Expedited Approval Scheme

Published on January 21, 2022

Trial Scheme Found to Expedite Market Access

On January 17, 2022, the Medical Device Division (MDD) notified all Local Responsible Persons (LRP) of the formalization of the Expedited Approval Scheme that had previously been in trial format. Class II, III, and IV applications are eligible for the expedited scheme and it’s expected to shorten review times and expedite market access for qualifying products. Along with other factors, products will need to be approved by 2 or more Reference countries which includes founding members of the GHTF plus China. The MDD’s formal guidance, GN-02, can be found here.

Expedited Approval Scheme Eligibility

The Expedited Approval Scheme is meant help improve the review process in Hong Kong as review timelines increased the last couple of years. Class II, III, and IV products approved by any 2 of the following markets are eligible for a quicker review:

  • United States (U.S. Food and Drug Administration)
  • Canada (Health Canada)
  • Europe (Member countries of the European Union that have implemented the European Council Directives or Regulations on medical devices)
  • Japan (Ministry of Health, Labour and Welfare)
  • Australia (The Therapeutic Goods Administration) – Cannot have been approved through the EU Mutual Recognition route.
  • China (National Medical Products Administration)

With regard to adverse event requirements, the product must not have:

  1. any reported deaths or serious injuries associated with the device (locally and worldwide)
  2. any active recalls, field safety corrective actions or adverse events (locally and worldwide)

It will be very important that the leveraged approvals cover the same make and models being applied for in Hong Kong. Manufacturers will be expected to respond to any MDD queries arising during the review process within 2 weeks.

Unlike during the trial period, manufacturers do not need to provide evidence of a substantially equivalent product already on the market. This change simplifies the application process and benefits manufacturers with innovative or novel products. The MDD has also removed the trial limit on the number of expedited scheme applications one LRP could have at one time.

Leveraging Approvals to Avoid CAB Reviews

Manufacturers can now leverage medical devices approvals from 7 countries as evidence of the Essential Principles (TR-004). This saves time and money by avoiding an additional review by a Conformity Assessment Body (CAB) and includes approvals from the US, Canada, Europe, Australia, Japan, and China. Medical device approvals issued by Korea’s MFDS are also being accepted on a trial basis until the end of 2022. Lastly, the MDD announced that they will accept, on a trial basis, IVD approvals issued by China’s NMPA as evidence of the Essential Principles as well.

Overview of the Hong Kong Registration Process

Medical Device product registration in Hong Kong is managed by the Medical Device Division (MDD) of the Department of Health, formerly known as the Medical Device Control Office (MDCO). Currently, medical device product registration is voluntary in Hong Kong for Class II and above medical devices and Class D IVD devices. While registration is voluntary, the Hospital Authority requires, or gives preference to, registered medical devices during public hospital tenders. Devices can be registered voluntarily through the Medical Device Administrative Control System (MDACS).

While manufacturers can use a Conformity Assessment Body (CAB) to review their technical documents, most manufacturers will leverage a Reference Country approval to expedite market access. ISO 13485 or equivalent is also required and listings are valid for 5 years with an administrative review.

For the latest registration information, including timelines and fees, see our Medical Device Registration page.

Important Documents and Application Forms

Schemes Scopes Guidance Notes Application Forms
Expedited Approval Scheme Class II/III/IV General Medical Device GN-02 MD-C2&3&4
Accepting marketing approvals obtained from the NMPA Class II/III/IV General Medical Device GN-02 MD-C2&3&4
Trial schemes for accepting marketing approvals obtained from the NMPA Class B/C/D In Vitro Diagnostic Medical Device GN-06 MD-IVD-Trial
Trial Scheme accepting marketing approvals obtained from the MFDS Class II/III/IV General Medical Device GN-02 MD-C2&3&4-Trial

Grow with Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in each market. Contact Asia Actual today with any questions related to medical device registration in Hong Kong or throughout the region.

Blog Posts

CDSCO Issues Updates to IVD Classification List in India

The Central Drugs Standard Control Organisation (CDSCO) of India issued a notice (PDF) on October 25, 2023 classifying in-vitro diagnostic (IVD) medical devices under medical device rules. The updates to IVD classification in India include intended use, associated risk, and other parameters.

Embracing Innovation and Collaboration: Highlights from the 15th CII Global MedTech Summit

On October 6, 2023, a team of enthusiastic members from the AAI (Artificial Intelligence and Innovation) group, including Ashoniya Puri, Sanjay Singh, and Rajat Budhori, had the honor of attending the prestigious 15th CII Global MedTech Summit. Hosted by the Confederation of Indian Industry (CII), one of India's largest industry bodies, this event brought together key players in the MedTech sector, both from India and abroad. The summit revolved around the central theme, "Paving the way for a USD 50 billion MedTech Industry by 2030," signifying a collective vision for the industry's future growth.


On September 18, 2023, The Directorate General of Drug Administration (DGDA) published the Drug and Cosmetics Act 2023 formalizing the regulatory requirements of medical and diagnostic devices in Bangladesh with immediate effect.  A translated version of the document is available on Asia Actual’s website here.  All medical devices now require a Marketing Authorization Certificate to clear Customs and be sold on the market in Bangladesh.